Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications

Diabetes

Volumn 54, Issue 1, 2005, Pages 234-242

  Obrosova, Irina G ^a,b   Pacher, Pal ^c   Szabó, Csaba ^d   Zsengeller, Zsuzsanna ^d   Hirooka, Hiroko ^e   Stevens, Martin J ^a   Yorek, Mark A ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INOTEK CORPORATION   (United States)

^e Drug Devmt Research Laboratories   (Japan)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALDEHYDE REDUCTASE; ASCORBIC ACID; FIDARESTAT; GLUCOSE; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SORBITOL; STREPTOZOCIN; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; HINDLIMB; HYPERGLYCEMIA; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MOTOR NERVE CONDUCTION; NITROSATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA; SCHWANN CELL; SCIATIC NERVE; SENSORY NERVE CONDUCTION; TISSUE SECTION;

ALDEHYDE REDUCTASE; ANIMALS; AORTA; ARTERIOLES; CATTLE; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; FRUCTOSE; IMIDAZOLIDINES; MALE; MOTOR NEURONS; NEURAL CONDUCTION; NEURONS, AFFERENT; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; SCIATIC NERVE; SORBITOL; TYROSINE;

EID: 12144279066     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.1.234     Document Type: Article

References (65)

1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. Oates PJ, Mylari BL: Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 8:2095-2119, 1999
4. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16:123-125, 2002
5. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T: Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 17:374-379, 2003
6. Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50:37-57, 2002
7. Vlassara H, Palace MR: Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 70:232-241, 2003
8. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N, Hotta N: A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095, 1999
9. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945-959, 2001
10. Obrosova IG: How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 50:3-35, 2002
11. Pennathur S, Heinecke JW: Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 9:565-574, 2004
12. Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P, Tomlinson DR: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 15:2508-2514, 2001
13. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113, 2001
14. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjati K, Pacher P, Szabo C, Stevens MJ: Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711-720, 2004
15. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452, 2004
16. Lou MF, Dickerson JE Jr, Garadi R, York BM Jr: Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res 46:517-530, 1988
17. Obrosova IG, Fathallah L: Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study. Diabetologia 43:1048-1055, 2000
18. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S: Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44:677-680, 1995
19. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52:864-871, 2003
20. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB: High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44:3135-3143, 2003
21. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001.
22. Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S: Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract 50:77-85, 2000
23. Price SA, Agthong S, Middlemas AB, Tomlinson DR: Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 53:1851-1856, 2004
24. Amano S, Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, Takeuchi M: Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 299:183-188, 2002
25. Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K, Kasuya Y, Yasuda Y, Kamiya H, Hotta N: The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 60:1-9, 2003
26. Obrosova IG, Fathallah L, Lang HJ, Greene DA: Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 42:1187-1194, 1999
27. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50:1927-1937, 2001
28. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic neuropathy. Diabetes 53:2404-2411, 2004
29. Kern TS, Engerman RL: Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 13:863-867, 1994
30. Kador PF, Takahashi Y, Wyman M, Ferris F 3rd: Diabetes like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 113:352-354, 1995
31. Thomas TP, Porcellati F, Kato K, Stevens MJ, Sherman WR, Greene DA: Effects of glucose on sorbitol pathway activation, cellular redox, and metabolism of myo-inositol, phosphoinositide, and diacylglycerol in cultured human retinal pigment epithelial cells. J Clin Invest 93:2718-2724, 1994
32. Stevens MJ, Hosaka Y, Masterson JA, Jones SM, Thomas TP, Larkin DD: Down-regulation of the human taurine transporter by glucose in cultured retinal pigment epithelial cells. Am J Physiol 277:E760-E771, 1999
33. Song Z, Fu DT, Chan YS, Leung S, Chung SS, Chung SK: Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23:638-647, 2003
34. Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy: Zenarestat Study Group. Neurology 53:580-591, 1999
35. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, the SNK-860 Diabetic Neuropathy Study Group: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24:1776-1782, 2001
36. Kador PF: The contributions of Jin H. Kinoshita to aldose reductase research. Exp Eye Res 50:615-620, 1990
37. Sima AA, Dunlap JA, Davidson EP, Wiese TJ, Lightle RL, Greene DA, Yorek MA: Supplemental myo-inositol prevents L-fucose-induced diabetic neuropathy. Diabetes 46:301-306, 1997
38. Kuruvilla R, Eichberg J: Depletion of phospholipid arachidonoyl- containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor. J Neurochem 71:775-783, 1998
39. Ohi T, Saita K, Furukawa S, Ohta M, Hayashi K, Matsukura S: Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. Exp Neurol 151:215-220, 1998
40. Gupta S, Chough E, Daley J, Oates P, Tomheim K, Ruderman NB, Keaney JF Jr: Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity. Am J Physiol Cell Physiol 282:C560-C566, 2002
41. Virag L, Szabo E, Gergely P, Szabo C: Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention (Review). Toxicol Lett 140-141:113-124, 2003
42. Lee AY, Chung SS: Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13:23-30 1999
43. Phillips SA, Mirrlees D, Thornalley PJ: Modification of the glyoxalase system in streptozotocin-induced diabetic rats: effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 46:805-811, 1993
44. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS: Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31:1358-1363, 2003
45. Nagaraj RH, Prabhakaram M, Ortwerth BJ, Monnier VM: Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase. Diabetes 43:580-586, 1994
46. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N: Epalrestat, an aldose reductase ihibitor, reduces the levels of Nε-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23:1539-1544, 2000
47. Yan SF, Ramasamy R, Naka Y, Schmidt AM: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169, 2003
48. Keogh RJ, Dunlop ME, Larkins RG: Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 46:41-47, 1997
49. Yamagishi S, Uehara K, Otsuki S, Yagihashi S: Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 87:497-507, 2003
50. Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K, Yasuda Y, Kato K, Hotta N: Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 44:480-487, 2001
51. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14 (Suppl. 3):S227-S232, 2003
52. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C: The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514-521, 2002
53. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C: Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 14:55-64, 2004
54. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A: Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680-2686, 2002
55. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057, 2003
56. Ou P, Nourooz-Zadeh J, Tritschler HJ, Wolff S: Activation of aldose reductase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. Free Radic Res 25:337-346, 1996
57. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA: Effects of DL-α-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49:1006-1015, 2000
58. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, Frank RN, Stevens MJ: Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102-1010, 2001
59. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, Obrosova IG: Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47:710-717, 2004
60. Zatechka DS Jr, Kador PF, Garcia-Castineiras S, Lou MF: Diabetes can alter the signal transduction pathways in the lens of rats. Diabetes 52:1014-1022
61. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 99:3270-3275, 2002
62. Yang SH, Sharrocks AD, Whitmarsh AJ: Transcriptional regulation by the MAP kinase signaling cascades. Gene 320:3-21, 2003
63. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG: Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17:1514-1516, 2003
64. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, Stevens MJ: Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51:2619-2628, 2002
65. Baumgartner-Parzer SM: Glycemia and regulation of endothelial adhesion molecules. Horm Metab Res 29:636-638, 1997